Molecure S.A. (MOC.WA)
PLN 10.0
(-1.96%)
PLN 10.0
(-1.96%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -56.84 Million PLN | 3.99% |
| 2022 | -59.2 Million PLN | 38.34% |
| 2021 | -96.03 Million PLN | 16.69% |
| 2020 | -115.27 Million PLN | -281.53% |
| 2019 | -30.21 Million PLN | 41.74% |
| 2018 | -51.86 Million PLN | -293.02% |
| 2017 | -13.19 Million PLN | -422.31% |
| 2016 | -2.52 Million PLN | 62.22% |
| 2015 | -6.68 Million PLN | -192.64% |
| 2014 | -2.28 Million PLN | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -45.74 Million PLN | 19.53% |
| 2024 Q2 | -32.02 Million PLN | 30.0% |
| 2024 Q3 | -26.96 Million PLN | 28.12% |
| 2023 Q2 | -44.34 Million PLN | 6.57% |
| 2023 Q3 | -80.29 Million PLN | -81.06% |
| 2023 Q4 | -56.84 Million PLN | 29.2% |
| 2023 FY | -56.84 Million PLN | 3.99% |
| 2023 Q1 | -47.46 Million PLN | 19.84% |
| 2022 Q3 | -75.51 Million PLN | 2.7% |
| 2022 Q2 | -77.61 Million PLN | 12.08% |
| 2022 FY | -59.2 Million PLN | 38.34% |
| 2022 Q1 | -88.27 Million PLN | 8.08% |
| 2022 Q4 | -59.2 Million PLN | 21.59% |
| 2021 Q4 | -96.03 Million PLN | 4.74% |
| 2021 Q3 | -100.81 Million PLN | 4.73% |
| 2021 Q2 | -105.81 Million PLN | 8.02% |
| 2021 FY | -96.03 Million PLN | 16.69% |
| 2021 Q1 | -115.04 Million PLN | 0.2% |
| 2020 Q1 | -26.83 Million PLN | 11.19% |
| 2020 Q2 | -26.9 Million PLN | -0.27% |
| 2020 FY | -115.27 Million PLN | -281.53% |
| 2020 Q4 | -115.27 Million PLN | -396.68% |
| 2020 Q3 | -23.2 Million PLN | 13.74% |
| 2019 Q4 | -30.21 Million PLN | 14.35% |
| 2019 FY | -30.21 Million PLN | 41.74% |
| 2019 Q3 | -35.27 Million PLN | 6.25% |
| 2019 Q2 | -37.62 Million PLN | 11.29% |
| 2019 Q1 | -42.41 Million PLN | 18.22% |
| 2018 Q4 | -51.86 Million PLN | 9.36% |
| 2018 FY | -51.86 Million PLN | -293.02% |
| 2018 Q1 | -9.66 Million PLN | 26.73% |
| 2018 Q2 | -62.52 Million PLN | -546.59% |
| 2018 Q3 | -57.21 Million PLN | 8.48% |
| 2017 Q2 | -14.04 Million PLN | -655.97% |
| 2017 FY | -13.19 Million PLN | -422.31% |
| 2017 Q3 | -14.26 Million PLN | -1.59% |
| 2017 Q4 | -13.19 Million PLN | 7.52% |
| 2017 Q1 | 2.52 Million PLN | 200.0% |
| 2016 Q4 | -2.52 Million PLN | 0.0% |
| 2016 FY | -2.52 Million PLN | 62.22% |
| 2016 Q1 | 6.68 Million PLN | 0.0% |
| 2015 FY | -6.68 Million PLN | -192.64% |
| 2014 FY | -2.28 Million PLN | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioceltix S.A. | -9.13 Million PLN | -522.303% |
| BIOTON S.A. | 64.81 Million PLN | 187.716% |
| Captor Therapeutics Spolka Akcyjna | -71.92 Million PLN | 20.962% |
| Mabion S.A. | -11.98 Million PLN | -374.174% |
| NanoGroup S.A. | -537.61 Thousand PLN | -10474.308% |
| Pharmena S.A. | -22.05 Million PLN | -157.747% |
| Poltreg S.A. | -57.75 Million PLN | 1.573% |
| Pure Biologics Spólka Akcyjna | 9.33 Million PLN | 709.181% |
| Ryvu Therapeutics S.A. | -57.03 Million PLN | 0.323% |
| Synthaverse S.A. | 67.86 Million PLN | 183.764% |
| Urteste S.A. | -512 Thousand PLN | -11003.271% |